Institute of Medicine Recommendations for The Prevention and Control of Hepatitis B and C

被引:153
作者
Mitchell, Abigail E. [1 ]
Colvin, Heather M. [1 ]
Beasley, R. Palmer [2 ]
机构
[1] Natl Acad, Inst Med, Board Populat Hlth & Publ Hlth Practice, Washington, DC 20001 USA
[2] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol & Dis Control, Houston, TX USA
关键词
VIRAL-HEPATITIS; VIRUS-INFECTION; UNITED-STATES; INJECTION; TIME;
D O I
10.1002/hep.23561
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite federal, state, and local public health efforts to prevent and control hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, these diseases remain serious health problems in the United States. About 1%-2% of the U.S. population has chronic HBV or HCV infections, and each year about 15,000 people die from liver cancer or liver disease related to these preventable infections. The Institute of Medicine formed an expert committee to determine ways to reduce new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis and released its findings in a report. The major factor found to impede current efforts to prevent and control HBV and HCV is lack of knowledge and awareness about these diseases among healthcare and social-service providers, members of the public, and policy makers. Because the extent and seriousness of this public health problem is not appreciated, inadequate resources are being allocated to prevention, control, and surveillance programs. This situation has led to continued transmission of HBV and HCV and inadequate identification of and medical management for chronically infected people. Conclusion: To address the situation, the Institute of Medicine report makes recommendations in four areas: improved surveillance for HBV and HCV; improved knowledge and awareness among healthcare and social-service providers and the public, especially at-risk people; improved HBV vaccine coverage; and improved viral hepatitis services and access to those services. (HEPATOLOGY 2010;51:729-733)
引用
收藏
页码:729 / 733
页数:5
相关论文
共 8 条
  • [1] Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004
    Amon, Joseph J.
    Garfein, Richard S.
    Ahdieh-Grant, Linda
    Armstrong, Gregory L.
    Ouellet, Lawrence J.
    Latka, Mary H.
    Vlahov, David
    Strathdee, Steffanie A.
    Hudson, Sharon M.
    Kerndt, Peter
    Jarlais, Don Des
    Williams, Ian T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) : 1852 - 1858
  • [2] [Anonymous], VIR HEP STAT SURV
  • [3] Daniels Danni, 2009, Morbidity and Mortality Weekly Report, V58, P1
  • [4] Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place
    Hagan, Holly
    Pouget, Enrique R.
    Des Jarlais, Don C.
    Lelutiu-Weinberger, Corina
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 168 (10) : 1099 - 1109
  • [5] Self-reported hepatitis C virus antibody status and risk behavior in young injectors
    Hagan, Holly
    Campbell, Jennifer
    Thiede, Hanne
    Strathdee, Steffanie
    Ouellet, Lawrence
    Kapadia, Farzana
    Hudson, Sharon
    Garfein, Richard S.
    [J]. PUBLIC HEALTH REPORTS, 2006, 121 (06) : 710 - 719
  • [6] IOM (Institute of Medicine), 2010, HEP LIV CANC NAT STR
  • [7] Why we should routinely screen Asian American adults for hepatitis B: A cross-sectional study of Asians in California
    Lin, Steven Y.
    Chang, Ellen T.
    So, Samuel K.
    [J]. HEPATOLOGY, 2007, 46 (04) : 1034 - 1040
  • [8] Time for renewed commitment to viral hepatitis prevention
    Ward, John W.
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2008, 98 (05) : 779 - 781